ATN 015: SHORT-CYCLE THERAPY IN ADOLESCENTS WITH ESTABLISHED VIRAL SUPPRESSION

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项第二阶段的艾滋病毒艾滋病研究旨在获得有关青少年短周期疗法(SCT)概念的初步安全性数据。这项研究的主要目的是测试安全性假设，即与持续高度抗逆转录病毒治疗(HAART)的受试者相比，SCT受试者的病毒载量反弹不会增加。作为一项第二阶段研究，其目标是在现有生物行为数据严格定义的少数受试者中，以有效和精确的方式证明SCT的安全性和初步疗效。这项研究的主要目的是比较病毒载量抑制(病毒载量反弹时的1000拷贝/毫升将被评估)。比较的时间是从研究开始到研究结束(24周)。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This Phase II HIV AIDS study is designed to obtain preliminary safety data on the concept of short cycle therapy (SCT) in adolescents. The primary objective of this study is to test the safety hypothesis that viral load rebound will not be increased in subjects on SCT compared to subjects on continuous highly antiretroviral therapy (HAART). As a Phase II study, its objective is to demonstrate with efficiency and precision the safety and preliminary efficacy of SCT in a small number of subjects tightly-defined by existing bio-behavioral data. The main aim of this study is to compare viral load suppression ( 1,000 copies/ml at time of viral load rebound will be assessed. The comparison period will be from study entry to administrative end of the study (24 weeks).